Goodpasture Syndrome: Management When Anti-GBM Antibodies Persist After Cyclophosphamide
This protocol addresses Goodpasture syndrome in the specific situation where initial first-line immunosuppressive therapy has not achieved the expected clinical targets — most critically, where anti-GBM antibodies remain detectable and alveolar hemorrhage has not resolved.
Previous Line — Failure Condition
Initial treatment with
cyclophosphamide (combined with glucocorticoids and plasma exchange) did not meet the required goals:
- Clearance of anti-GBM antibodies within 8 weeks
- Recovery from alveolar hemorrhage
This protocol defines the structured next step after that failure.
Next-Line Approach — Partial Overview
When anti-GBM antibodies persist beyond the initial cyclophosphamide course, continued immunosuppressive therapy — using an alternative maintenance agent in combination with glucocorticoids — is the recommended strategy. The full protocol specifies the agent options, monitoring criteria, and clinical decision points.
References
DOI: 10.1038/kisup.2012.27
In patients with persistent anti-GBM antibody after 3 months of cyclophosphamide, continuation of treatment with either azathioprine or mycophenolate (in combination with glucocorticoids) is suggested.
View source ↗